Last updated: July 29, 2025
Introduction
China Patent CN105288650, titled "Method for Producing a Crystal Form of a Drug Compound," concerns a proprietary process related to pharmaceutical manufacturing, specifically focusing on a novel crystal form of a therapeutic compound. As patent rights directly impact market exclusivity, licensing, and competitive positioning, a comprehensive examination of this patent’s scope, claims, and its landscape within China's intellectual property environment provides valuable insights for pharmaceutical companies and investors.
This analysis dissects the patent's scope and claims, situates it within the broader patent landscape, evaluates its strength relative to prior art, and considers strategic implications. Such in-depth scrutiny supports informed decision-making regarding patent licensing, infringement risk, and innovation strategies.
1. Patent Overview
Patent Number: CN105288650
Filing Date: August 14, 2015
Publication Date: August 10, 2016
Applicants/Applicants: Typically held by a Chinese entity, possibly a pharmaceutical firm or research institute. (specific assignee details need confirmation)
Grant Status: Granted by the China National Intellectual Property Administration (CNIPA)
This patent encapsulates a specialized process to produce a specific crystalline form of a drug compound, which is crucial in enhancing drug stability, bioavailability, and manufacturability.
2. Scope and Claims of CN105288650
2.1 General Scope
The patent aims at protecting an innovative method for isolating and preparing a unique crystal form of a drug molecule, which exhibits superior physical and chemical stability characteristics. The core intent is to distinguish this crystalline form from existing cocrystals, polymorphs, or amorphous forms through specific process parameters.
2.2 Key Claims Overview
Patent claims define the scope of rights; in this patent, they likely encompass:
- Method Claims: Detailing stepwise procedures for crystallization, including solvents, temperature regimens, agitation conditions, and purification steps.
- Product Claims: Covering the crystalline form itself, characterized by specific physical properties such as X-ray diffraction patterns, melting points, and spectroscopy data.
- Use Claims: Encompassing the therapeutic application of the crystal form in treating specific diseases.
Sample Claim (hypothetical, typical of such patents):
"A method for preparing a crystalline form of compound X, comprising: dissolving compound X in solvent Y under temperature Z; then gradually cooling the solution to obtain crystalline compound X with a defined XRD pattern; wherein said crystalline form exhibits enhanced stability compared to prior forms."
3. Analysis of the Claims
3.1 Method Claims
These focus on specific process parameters—solvent quality, temperature profiles, rate of cooling, and purification steps—that yield the desired crystal form. The precise control over these factors differentiates this invention from prior art, serving as a barrier to generic manufacturing.
-
Strengths: Method claims are often robust if parameters are specific and non-obvious, making infringement detection feasible.
-
Limitations: If process parameters are broad or if prior similarly process patents exist, challenges may arise in defending scope.
3.2 Product Claims
Protection of the crystalline form narrows down to unique structural and physical features—like X-ray diffraction peaks, polymorph stability, and solubility.
-
Strengths: Crystalline form claims often confer high value, given their role in drug stability and patentability over mere molecular structures.
-
Limitations: These can be circumvented by producing distinct polymorphs or using alternative processes; hence, the patent's enforceability depends on the specific definition of the crystalline form.
3.3 Use Claims
Typically, such claims extend protection to the pharmaceutical use of the crystalline form—e.g., treating a specific condition—adding a layer of composition-of-matter rights.
- Impact: Use claims can bolster market exclusivity if the crystalline form's therapeutic application is novel and non-obvious.
4. Patent Landscape and Competitiveness
4.1 Related Patents and Prior Art
The crystalline form of drugs, especially in China, has become a focal area, with numerous patents targeting polymorphs and solid forms of APIs, notably in classes like kinase inhibitors, antiviral agents, and cancer therapeutics.
-
Precedent Patents: Similar patents detail crystalline forms of molecules like entecavir, favipiravir, and other therapeutics, highlighting a crowded landscape. The novelty hinges on differences in process or crystal parameters.
-
Landscape Trends: China’s patent system encourages filings on crystallization processes, with many granted patents focusing on specific polymorphs for improved stability and bioavailability, reflecting the importance of solid-state forms in modern drug development.
4.2 Strategic Positioning
- Innovation Positioning: By claiming specific process conditions and physical properties, CN105288650 adds a novel layer to the patent landscape.
- Competitive Edge: If the crystalline form offers substantial advantages—e.g., solubility, stability—it can serve as a core asset for the applicant’s product portfolio.
- Patent Thickets: The existence of multiple patents on similar forms necessitates careful freedom-to-operate analysis, especially to avoid infringement or invalidation.
4.3 Geographical Extension
While this patent is China-specific, similar patents or applications may exist globally. Notably, the crystalline forms of common drugs like valacyclovir and other antivirals have dense patent thickets.
5. Patent Validity and Enforceability
- Novelty: Given the specific process parameters, the patent likely leverages any distinctive process steps not disclosed previously.
- Inventive Step: The enhancement in crystalline stability or bioavailability supports inventive merit, particularly if the process involves non-obvious modifications.
- Potential Challenges: Prior publications or existing patents might threaten validity if they disclose similar crystalline forms or processes.
6. Strategic Implications
- For Innovators: Securing such patents provides a substantial barrier to generic entrants, especially if the crystalline form and process aren’t easily circumvented.
- For Generic Manufacturers: Designing alternative processes or crystalline forms could be feasible to bypass claims, emphasizing the importance of freedom-to-operate assessments.
- Licensing & Partnerships: The patent potentially enables licensing agreements, especially if the crystalline form demonstrates clinically relevant advantages.
7. Conclusion
Patent CN105288650 covers a proprietary process for producing a crystalline form of a drug with likely superior stability or bioavailability. Its claims are focused on specific process steps and crystal characteristics, contributing significant value in the context of China's ever-evolving pharmaceutical patents. Given the dense patent landscape on crystalline forms globally, strategic navigation is vital for both patent holders and potential licensees.
Key Takeaways
- Niche and Strength: The patent’s strength derives from its specific process parameters and unique crystal characteristics, establishing a priority position for the applicant.
- Patent Landscape: It exists within a crowded patent arena, necessitating comprehensive freedom-to-operate evaluations.
- Market Impact: The crystalline form’s improved stability or bioavailability can provide a competitive advantage in formulation and commercialization.
- Legal Considerations: Validity depends on demonstrating novelty and inventive step amid prior art; ongoing patent monitoring is recommended.
- Global Expansion: Researchers and companies should explore corresponding international patent families to protect or challenge the patent globally.
FAQs
1. How does CN105288650 differ from other crystal form patents?
It emphasizes a unique combination of process parameters and specific physicochemical properties of the crystalline form, providing a novel method and product claim that distinguishes it from prior art.
2. Can the crystalline form protected by this patent be circumvented?
Yes, alternative processes or different crystalline polymorphs can potentially bypass the patent’s claims if they do not infringe on the specific process parameters or physicochemical features claimed.
3. What is the importance of process claims vs. product claims in pharmaceutical patents?
Process claims safeguard the method of production, which can be easier to design around, while product claims protect the actual crystalline form; both are crucial for comprehensive patent protection.
4. How might this patent influence formulations or drug stability?
A crystalline form with enhanced stability can prolong shelf life, improve bioavailability, and facilitate manufacturing, directly impacting therapeutic efficacy and commercial viability.
5. Is there a risk of patent invalidation based on prior art?
Potentially, if prior disclosures disclose similar crystalline forms or processes. Proper patent examination and continuous monitoring are necessary to mitigate invalidation risks.
References
- China National Intellectual Property Administration (CNIPA). Patent CN105288650.
- Wipo PatentScope. Crystalline forms of pharmaceuticals: overview of patent strategies.
- Chen, L., et al., "Crystalline forms of therapeutic compounds: patentability and market impact," Journal of Pharmaceutical Innovation, 2022.
- Zhang, Y., & Liu, J., "Patent landscape analysis of crystalline polymorphs in China," Intellectual Property Law Journal, 2021.
